Ajax Set To ‘Attack JAK’ In Myelofibrosis With $95m In Series C Cash
Will Advance Myeloproliferative Neoplasm Pipeline
Ajax Therapeutics plans to take its type II JAK2 inhibitor into the clinic during the second half of 2024 with the aim of modifying disease in a way that first-generation type I inhibitors do not.
